Work

122eP Preclinical investigation of the potential synergistic action of small molecule inhibitors in combination with chemotherapy in colon and liver cancer cells

Year: 2026

Type: article

Abstract: Colon and liver cancers are among the most prevalent malignancies worldwide in both sexes. Cisplatin is a widely used chemotherapeutic agent; however, its clinical effectiveness is limited by the development of resistance and toxicity. Cisplatin acts primarily through DNA crosslinking, resulting in DNA damage, cell-cycle arrest, and apoptosis. Enhancing its therapeutic impact through combination strategies, allows for lower effective dosage. Targeting the PI3K/AKT/mTOR pathway, a key regulator of cell survival often upregulated in cancer, using small-molecule inhibitors (SMIs) has shown promise.

Source: ESMO Open

DOI: 10.1016/j.esmoop.2026.106263

Authors: C.M. Neophytou, E. Koulermou, M. Christou

Institution: European University Cyprus

Language: English

Topic: PI3K/AKT/mTOR signaling in cancer

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $3,910